Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors

M Cucchiarini1, X L Ren, G Perides

  • 1Harvard Institutes of Medicine and Beth Israel Deaconess Medical Center, Boston, MA, USA.

Gene Therapy
|April 15, 2003
PubMed

Insights

Researchers developed a new method for gene delivery specifically to microglia, the brain's immune cells. Using adeno-associated virus (AAV) vectors with an F4/80 promoter, they achieved highly selective gene expression in microglia.

Area of Science:

  • Neuroscience
  • Gene Therapy
  • Cell Biology

Background:

  • Microglia are key immune cells in the central nervous system.
  • Microglia are implicated in brain disorders.
  • Targeting microglia is crucial for research and therapy.

Purpose of the Study:

  • To evaluate adeno-associated virus (AAV) vectors for selective microglia targeting.
  • To identify cell-type-specific transcriptional elements for microglia gene expression.

Main Methods:

  • Utilized two adeno-associated virus (AAV) serotypes.
  • Examined various cell-type-specific transcriptional elements.
  • Assessed gene expression selectivity in vitro and in vivo.
  • Focused on an element from the murine macrophage marker F4/80 gene.

Main Results:

  • An F4/80-derived element demonstrated high selectivity for microglia.
  • Gene expression was specifically targeted to microglia using AAV vectors.
  • This marks the first use of AAV vectors for selective gene transfer in microglia.
  • First-time use of recombinant AAV-5 vectors in any macrophage lineage.

Conclusions:

  • The F4/80 promoter enables highly selective gene transfer to microglia.
  • AAV vectors with the F4/80 promoter are promising for microglia-targeted gene therapy.
  • This approach facilitates research into brain pathologies and therapeutic development.

Related Concept Videos